Skin and soft tissue infections

Staphylococci in Human Disease: Second Edition

Volumn , Issue , 2009, Pages 378-394

  Stryjewski, Martin E ^a,b   Nannini, Esteban C ^c   Corey, G Ralph ^b  

^a CEMIC   (Argentina)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Bullous impetigo and staphylococcal scalded skin syndrome (SSSS); Folliculitis, furuncles, and carbuncles; Hidradenitis suppurativa Verneuil's disease or acne inverse; Incidence of impetigo; National ambulatory medical care surveys (NAMCS) and National Hospital Ambulatory Medical Care Surveys (NHAMCS); Necrotizing fasciitis uncommon life threatening infection; Skin and soft tissue infections; Skin and soft tissue infections due to MRSA; Staphylococcus aureus pathogen in skin and soft tissue infections (SSTIs); Staphylococus aureus skin and skin structure related abscesses

Indexed keywords

EID: 84890762497     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444308464.ch19     Document Type: Chapter

References (225)

1. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006;12:1715-23.
2. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006;144:368-70.
3. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillinresistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17.
4. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillinresistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.
5. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777-84.
6. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
7. Miller LG, Quan C, Shay A et al. A prospective investigation of outcomes after hospital discharge for endemic, communityacquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007;44:483-92.
8. Centers for Disease Control and Prevention, National Center for Health Statistics. Vital and Health Statistics. National Hospital Discharge Survey: 2004 Annual Summary with Detailed Diagnosis and Procedure Data. U.S. Department of Health and Human Services 2006;13[162].
9. Koning S, Mohammedamin RS, van der Wouden JC, van Suijlekom-Smit LW, Schellevis FG, Thomas S. Impetigo: incidence and treatment in Dutch general practice in 1987 and 2001. Results from two national surveys. Br J Dermatol 2006; 154:239-43.
10. Schachner LA. Treatment of uncomplicated skin and skin infections in the pediatric and adolescent patient populations. J Drugs Dermatol 2005;4(6 suppl):s30-s33.
11. Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990;144: 1313-15.
12. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1992;36:287-90.
13. Dajani AS, Ferrieri P, Wannamaker LW. Natural history of impetigo. II. Etiologic agents and bacterial interactions. J Clin Invest 1972;51:2863-71.
14. Koning S, van Belkum A, Snijders S et al. Severity of nonbullous Staphylococcus aureus impetigo in children is associated with strains harboring genetic markers for exfoliative toxin B, Panton-Valentine leukocidin, and the multidrug resistance plasmid pSK41. J Clin Microbiol 2003;41:3017-21.
15. Lopez FA, Lartchenko S. Skin and soft tissue infections. Infect Dis Clin North Am 2006;20:759-72, v-vi.
16. Koning S, van Suijlekom-Smit LW, Nouwen JL et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2002; 324:203-6.
17. Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev 2004;2:CD003261.
18. Mertz PM, Marshall DA, Eaglstein WH, Piovanetti Y, Montalvo J. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol 1989;125:1069-73.
19. Johnston GA. Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants. Expert Rev Anti Infect Ther 2004;2:439-46.
20. Yun HJ, Lee SW, Yoon GM et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003; 51:619-23.
21. Oranje AP, Chosidow O, Sacchidanand S et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007;215:331-40.
22. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician 2007;75:859-64.
23. Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994;11:293-303.
24. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol 1990;22:883-5.
25. Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, von Eiff C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 2003;41:1434-9.
26. Piemont Y, Rasoamananjara D, Fouace JM, Bruce T. Epidemio-logical investigation of exfoliative toxin-producing Staphylococcus aureus strains in hospitalized patients. J Clin Microbiol 1984;19:417-20.
27. Adesiyun AA, Lenz W, Schaal KP. Exfoliative toxin production by Staphylococcus aureus strains isolated from animals and human beings in Nigeria. Microbiologica 1991;14:357-62.
28. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000;6:1275-7.
29. Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002;110:53-60.
30. Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol Med Microbiol 2003;39:181-9.
31. Lina G, Gillet Y, Vandenesch F, Jones ME, Floret D, Etienne J. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis 1997;25:1369-73.
32. Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 2003;4:165-75.
33. Salopek TG. Nikolsky's sign: is it "dry" or is it "wet"? Br J Dermatol 1997;136:762- 7.
34. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand. Am J Pathol 2003;162:1515-20.
35. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.
36. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006;355: 1800-10.
37. Yamasaki O, Yamaguchi T, Sugai M et al. Clinical manifestations of staphylococcal scalded-skin syndrome depend on serotypes of exfoliative toxins. J Clin Microbiol 2005;43:1890-3.
38. El Helali N, Carbonne A, Naas T et al. Nosocomial outbreak of staphylococcal scalded skin syndrome in neonates: epidemiological investigation and control. J Hosp Infect 2005;61:130-8.
39. Yamaguchi T, Yokota Y, Terajima J et al. Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J Infect Dis 2002;185:1511-16.
40. Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol 2006; 44:2119-25.
41. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001; 33(suppl 2):S84-S93.
42. Wiese-Posselt M, Heuck D, Draeger A et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007;44:e88-e95.
43. Landen MG, McCumber BJ, Asam ED, Egeland GM. Outbreak of boils in an Alaskan village: a case-control study. West J Med 2000;172:235-9.
44. Decker MD, Lybarger JA, Vaughn WK, Hutcheson RH Jr, Schaffner W. An outbreak of staphylococcal skin infections among river rafting guides. Am J Epidemiol 1986;124:969-76.
45. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.
46. Moreillon P, Que Y, Glauser MP. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier Churchill Livingstone, 2005:2321- 51.
47. Bahrain M, Vasiliades M, Wolff M, Younus F. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2006;38:702-7.
48. Ebright JR, Pace MT, Niazi AF. Septic thrombosis of the cavernous sinuses. Arch Intern Med 2001;161:2671-6.
49. Talbot TR, Nania JJ, Wright PW, Jones I, Aronsky D. Evaluation of the microbiology of soft-tissue abscesses in the era of communityassociated strains of methicillin-resistant Staphylococcus aureus: an argument for empirical contact precautions. Infect Control Hosp Epidemiol 2007;28:730-2.
50. Entin MA. Infections of the hand. Surg Clin North Am 1964; 44:981-93.
51. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among communityrecruited injection drug users in San Francisco. Clin Infect Dis 2000;30:579-81.
52. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002;16:697-712.
53. Young DM, Harris HW, Charlebois ED et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg 2004;139: 947-51.
54. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006;141:850-4; discussion 855-6.
55. Brook I. Microbiology and management of infected neck cysts. J Oral Maxillofac Surg 2005;63:392-5.
56. Diven DG, Dozier SE, Meyer DJ, Smith EB. Bacteriology of inflamed and uninflamed epidermal inclusion cysts. Arch Dermatol 1998;134:49-51.
57. Poonawalla T, Uchida T, Diven DG. Survey of antibiotic prescription use for inflamed epidermal inclusion cysts. J Cutan Med Surg 2006;10:79-84.
58. Squire BT, Fox JC, Anderson C. ABSCESS: applied bedside sonography for convenient evaluation of superficial soft tissue infections. Acad Emerg Med 2005;12:601-6.
59. Grayson ML. The treatment triangle for staphylococcal infections. N Engl J Med 2006;355:724- 7.
60. Heilpern KL. Skin and soft tissue abscesses: the case for culturing abscess fluid. Ann Emerg Med 2007;50:64-6.
61. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977;64:264-6.
62. Llera JL, Levy RC. Treatment of cutaneous abscess: a doubleblind clinical study. Ann Emerg Med 1985;14:15-19.
63. Lee MC, Rios AM, Aten MF et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004;23:123-7.
64. Hankin A, Everett WW. Are antibiotics necessary after incision and drainage of a cutaneous abscess? Ann Emerg Med 2007; 50:49-51.
65. Rajendran PM, Young D, Maurer T et al. Randomized, doubleblind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007;51:4044-8.
66. Rajendran PM, Young DM, Maurer T, Chambers HF, Jacobson MA, Harris HW. Antibiotic use in the treatment of soft tissue abscesses: a survey of current practice. Surg Infect (Larchmt) 2007;8:237-8.
67. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004;350: 904-12.
68. Ellis Simonsen SM, van Orman ER, Hatch BE et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006;134:293-9.
69. Carratala J, Roson B, Fernandez-Sabe N et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003;22:151-7.
70. Bjornsdottir S, Gottfredsson M, Thorisdottir AS et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis 2005;41:1416-22.
71. Dupuy A, Benchikhi H, Roujeau JC et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591-4.
72. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996;23: 1162-4.
73. Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982; 97:493-6.
74. Baddour LM, Bisno AL. Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 1984;251:1049-52.
75. Baddour LM. Cellulitis syndromes: an update. Int J Antimicrob Agents 2000;14:113-16.
76. Woo PC, Lum PN, Wong SS, Cheng VC, Yuen KY. Cellulitis complicating lymphoedema. Eur J Clin Microbiol Infect Dis 2000;19:294-7.
77. Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis 1999;34:325-7.
78. Stryjewski ME, Hall RP, Chu VH et al. Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis. J Infect Dis 2007;196:1425-30.
79. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-5.
80. Peralta G, Padron E, Roiz MP et al. Risk factors for bacteremia in patients with limb cellulitis. Eur J Clin Microbiol Infect Dis 2006;25:619-26.
81. Rodriguez Ferran L, Puigarnau Vallhonrat R, Fasheh Youssef W, Ribo Aristazabal J, Luaces Cubells C, Pou Fernandez J. [Orbital and periorbital cellulitis. Review of 107 cases.] An Esp Pediatr 2000;53:567-72.
82. Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:322-45.
83. Rutar T, Chambers HF, Crawford JB et al. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology 2006;113:1455-62.
84. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992;93: 543-8.
85. Mertz KR, Baddour LM, Bell JL, Gwin JL. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. Clin Infect Dis 1998;26:481-6.
86. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999;29:1483-8.
87. McNamara DR, Tleyjeh IM, Berbari EF et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med 2007;167:709-15.
88. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989;149:293-6.
89. Sadow KB, Chamberlain JM. Blood cultures in the evaluation of children with cellulitis. Pediatrics 1998;101(3):e4.
90. Eron LJ, Lipsky BA. Use of cultures in cellulitis: when, how, and why? Eur J Clin Microbiol Infect Dis 2006;25:615-17.
91. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-74.
92. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997;29:377-82.
93. Wang JH, Liu YC, Cheng DL et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997;25:685-9.
94. Duvanel T, Merot Y, Harms M, Saurat JH. Prophylactic antibiotics in erysipelas. Lancet 1985;i:1401.
95. Green RJ, Dafoe DC, Raffin TA. Necrotizing fasciitis. Chest 1996;110:219-29.
96. Childers BJ, Potyondy LD, Nachreiner R et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg 2002;68:109-16.
97. McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-63; discussion 563-5.
98. Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995;33:2382-7.
99. Regev A, Weinberger M, Fishman M, Samra Z, Pitlik SD. Necrotizing fasciitis caused by Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1998;17:101- 3.
100. Hsieh WS, Yang PH, Chao HC, Lai JY. Neonatal necrotizing fasciitis: a report of three cases and review of the literature. Pediatrics 1999;103(4):e53.
101. Lee YT, Lin JC, Wang NC, Peng MY, Chang FY. Necrotizing fasciitis in a medical center in northern Taiwan: emergence of methicillin-resistant Staphylococcus aureus in the community. J Microbiol Immunol Infect 2007;40:335-41.
102. Dehority W, Wang E, Vernon PS, Lee C, Perdreau-Remington F, Bradley J. Community-associated methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a neonate. Pediatr Infect Dis J 2006;25:1080-1.
103. Mohammedi I, Ceruse P, Duperret S, Vedrinne J, Bouletreau P. Cervical necrotizing fasciitis: 10 years' experience at a single institution. Intensive Care Med 1999;25:829-34.
104. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352: 1445-53.
105. Morgan WR, Caldwell MD, Brady JM, Stemper ME, Reed KD, Shukla SK. Necrotizing fasciitis due to a methicillin-sensitive Staphylococcus aureus isolate harboring an enterotoxin gene cluster. J Clin Microbiol 2007;45:668-71.
106. Cheng NC, Chang SC, Kuo YS, Wang JL, Tang YB. Necrotizing fasciitis caused by methicillin-resistant Staphylococcus aureus resulting in death. A report of three cases. J Bone Joint Surg Am 2006;88:1107-10.
107. Omland LH, Rasmussen SW, Hvolris J, Friis-Moller A. Necrotizing fasciitis caused by TSST-1 producing penicillinsensitive Staphylococcus aureus: a case report. Acta Orthop 2007; 78:296-7.
108. Jarrett P, Ha T, Oliver F. Necrotizing fasciitis complicating disseminated cutaneous herpes zoster. Clin Exp Dermatol 1998;23:87-8.
109. Lee YT, Chou TD, Peng MY, Chang FY. Rapidly progressive necrotizing fasciitis caused by Staphylococcus aureus. J Microbiol Immunol Infect 2005;38:361-4.
110. Saliba WR, Goldstein LH, Raz R, Mader R, Colodner R, Elias MS. Subacute necrotizing fasciitis caused by gas-producing Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2003;22: 612-14.
111. Kalorin CM, Tobin EH. Community associated methicillin resistant Staphylococcus aureus causing Fournier's gangrene and genital infections. J Urol 2007;177:967-71.
112. Basoglu M, Gul O, Yildirgan I, Balik AA, Ozbey I, Oren D. Fournier's gangrene: review of fifteen cases. Am Surg 1997;63: 1019-21.
113. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg 2000;87:718-28.
114. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32:1535-41.
115. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 1984;310:1689-93.
116. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007;44:705-10.
117. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64:397-400.
118. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007;195:202-11.
119. Anaya DA, McMahon K, Nathens AB, Sullivan SR, Foy H, Bulger E. Predictors of mortality and limb loss in necrotizing soft tissue infections. Arch Surg 2005;140:151-7; discussion 158.
120. Small LN, Ross JJ. Tropical and temperate pyomyositis. Infect Dis Clin North Am 2005;19:981-9, x-xi.
121. Bickels J, Ben-Sira L, Kessler A, Wientroub S. Primary pyomyositis. J Bone Joint Surg Am 2002;84A:2277-86.
122. Crum NF. Bacterial pyomyositis in the United States. Am J Med 2004;117:420-8.
123. Chauhan S, Jain S, Varma S, Chauhan SS. Tropical pyomyositis (myositis tropicans): current perspective. Postgrad Med J 2004; 80:267-70.
124. Scriba J. Beitrang zur Aetiologie der myositis acuta. Deutche Zeit Chir 1885;22:497-502.
125. Levin MJ, Gardner P, Waldvogel FA. An unusual infection due to Staphylococcus aureus. N Engl J Med 1971;284:196-8.
126. Hsueh PR, Hsiue TR, Hsieh WC. Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clin Infect Dis 1996;22:858-60.
127. Gibson RK, Rosenthal SJ, Lukert BP. Pyomyositis. Increasing recognition in temperate climates. Am J Med 1984;77:768-72.
128. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO Jr, Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006;43:953-60.
129. Fowler A, Mackay A. Community-acquired methicillin-resistant Staphylococcus aureus pyomyositis in an intravenous drug user. J Med Microbiol 2006;55:123-5.
130. Cone LA, Lamb RB, Graff-Radford A et al. Pyomyositis of the anterior tibial compartment. Clin Infect Dis 1997;25:146-8.
131. Immerman RP, Greenman RL. Toxic shock syndrome associated with pyomyositis caused by a strain of Staphylococcus aureus that does not produce toxic-shock-syndrome toxin-1. J Infect Dis 1987;156:505-7.
132. Tumeh SS, Butler GJ, Maguire JH, Nagel JS. Pyogenic myositis: CT evaluation. J Comput Assist Tomogr 1988;12:1002- 5.
133. Karmazyn B, Kleiman MB, Buckwalter K, Loder RT, Siddiqui A, Applegate KE. Acute pyomyositis of the pelvis: the spectrum of clinical presentations and MR findings. Pediatr Radiol 2006;36:338-43.
134. Struk DW, Munk PL, Lee MJ, Ho SG, Worsley DF. Imaging of soft tissue infections. Radiol Clin North Am 2001;39:277- 303.
135. Lamki L, Willis RB. Radionuclide findings of pyomyositis. Clin Nucl Med 1982;7:465-7.
136. Gibberd GF. Sporadic and epidemic puerperal breast infections; a contrast in morbid anatomy and clinical signs. Am J Obstet Gynecol 1953;65:1038-41.
137. Faden H. Mastitis in children from birth to 17 years. Pediatr Infect Dis J 2005;24:1113.
138. Michie C, Lockie F, Lynn W. The challenge of mastitis. Arch Dis Child 2003;88:818-21.
139. Kaufmann R, Foxman B. Mastitis among lactating women: occurrence and risk factors. Soc Sci Med 1991;33:701-5.
140. Amir LH, Forster DA, Lumley J, McLachlan H. A descriptive study of mastitis in Australian breastfeeding women: incidence and determinants. BMC Public Health 2007;7:62.
141. Jonsson S, Pulkkinen MO. Mastitis today: incidence, prevention and treatment. Ann Chir Gynaecol Suppl 1994;208:84-7.
142. Foxman B, D'Arcy H, Gillespie B, Bobo JK, Schwartz K. Lactation mastitis: occurrence and medical management among breastfeeding women in the United States. Am J Epidemiol 2002;155:103-14.
143. Hager WD, Barton JR. Treatment of sporadic acute puerperal mastitis. Infect Dis Obstet Gynecol 1996;4:97-101.
144. Livingstone VH, Willis CE, Berkowitz J. Staphylococcus aureus and sore nipples. Can Fam Physician 1996;42:654-9.
145. Livingstone V, Stringer LJ. The treatment of Staphyloccocus aureus infected sore nipples: a randomized comparative study. J Hum Lact 1999;15:241-6.
146. Amir LH, Garland SM, Lumley J. A case-control study of mastitis: nasal carriage of Staphylococcus aureus. BMC Fam Pract 2006;7:57.
147. Osterman KL, Rahm VA. Lactation mastitis: bacterial cultivation of breast milk, symptoms, treatment, and outcome. J Hum Lact 2000;16:297-302.
148. Dener C, Inan A. Breast abscesses in lactating women. World J Surg 2003;27:130-3.
149. Thomsen AC, Espersen T, Maigaard S. Course and treatment of milk stasis, noninfectious inflammation of the breast, and infectious mastitis in nursing women. Am J Obstet Gynecol 1984;149:492-5.
150. Thomsen AC, Hansen KB, Moller BR. Leukocyte counts and microbiologic cultivation in the diagnosis of puerperal mastitis. Am J Obstet Gynecol 1983;146:938-41.
151. Barbosa-Cesnik C, Schwartz K, Foxman B. Lactation mastitis. JAMA 2003;289:1609-12.
152. Eidelman AI, Szilagyi G. Patterns of bacterial colonization of human milk. Obstet Gynecol 1979;53:550-2.
153. O'Hara RJ, Dexter SP, Fox JN. Conservative management of infective mastitis and breast abscesses after ultrasonographic assessment. Br J Surg 1996;83:1413-14.
154. Walsh M, McIntosh K. Neonatal mastitis. Clin Pediatr 1986;25: 395-9.
155. Stricker T, Navratil F, Forster I, Hurlimann R, Sennhauser FH. Nonpuerperal mastitis in adolescents. J Pediatr 2006;148:278-81.
156. Dahlbeck SW, Donnelly JF, Theriault RL. Differentiating inflammatory breast cancer from acute mastitis. Am Fam Physician 1995;52:929-34.
157. Berna-Serna JD, Madrigal M. Percutaneous management of breast abscesses. An experience of 39 cases. Ultrasound Med Biol 2004;30:1-6.
158. Reddy P, Qi C, Zembower T, Noskin GA, Bolon M. Postpartum mastitis and community-acquired methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2007;13:298-301.
159. Moazzez A, Kelso RL, Towfigh S, Sohn H, Berne TV, Mason RJ. Breast abscess bacteriologic features in the era of communityacquired methicillin-resistant Staphylococcus aureus epidemics. Arch Surg 2007;142:881-4.
160. Mortimer PS, Lunniss PJ. Hidradenitis suppurativa. J R Soc Med 2000;93:420-2.
161. Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999;140:90- 5.
162. Shah N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005;72:1547-52.
163. Winslow DJ. Botryomycosis. Am J Pathol 1959;35:153-67.
164. Neafie RC, Marty AM. Unusual infections in humans. Clin Microbiol Rev 1993;6:34-56.
165. Brunken RC, Lichon-Chao N, van der Broek H. Immunologic abnormalities in botryomycosis. A case report with review of the literature. J Am Acad Dermatol 1983;9:428-34.
166. Shapiro RL, Duquette JG, Nunes I et al. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am J Pathol 1997;150:359-69.
167. de Vries HJ, van Noesel CJ, Hoekzema R, Hulsebosch HJ. Botryomycosis in an HIV-positive subject. J Eur Acad Dermatol Venereol 2003;17:87-90.
168. Gavin PJ, Das L, Chadwick EG, Yogev R. Botryomycosis in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2000;19:900-1.
169. Yencha MW, Walker CW, Karakla DW, Simko EJ. Cutaneous botryomycosis of the cervicofacial region. Head Neck 2001;23: 594-8.
170. Chu WO, Fruauff A, Rivas R, Donovan V. Cutaneous botryomycosis: MR findings. AJR Am J Roentgenol 1994;163:647-8.
171. Schlossberg D, Pandey M, Reddy R. The Splendore-Hoeppli phenomenon in hepatic botryomycosis. J Clin Pathol 1998;51: 399-400.
172. Herchline TE, Ayers LW. Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol 1991;29:419-21.
173. Shittu A, Lin J, Morrison D, Kolawole D. Isolation and molecular characterization of multiresistant Staphylococcus sciuri and Staphylococcus haemolyticus associated with skin and soft-tissue infections. J Med Microbiol 2004;53:51-5.
174. Sanchez P, Buezas V, Maestre JR. [Staphylococcus lugdunensis infection: report of thirteen cases.] Enferm Infecc Microbiol Clin 2001;19:475-8.
175. Tan TY, Ng SY, Ng WX. Clinical significance of coagulasenegative staphylococci recovered from nonsterile sites. J Clin Microbiol 2006;44:3413-14.
176. Da Costa A, Lelievre H, Kirkorian G et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998;97:1791-5.
177. Wertheim HF, van Kleef M, Vos MC, Ott A, Verbrugh HA, Fokkens W. Nose picking and nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 2006;27:863-7.
178. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20.
179. Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5:751-62.
180. Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006;6:130.
181. Huang R, Mehta S, Weed D, Price CS. Methicillin-resistant Staphylococcus aureus survival on hospital fomites. Infect Control Hosp Epidemiol 2006;27:1267-9.
182. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
183. Kuehnert MJ, Kruszon-Moran D, Hill HA et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9.
184. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 1995;115:51-60.
185. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis 2004;39:806- 11.
186. Nouwen J, Boelens H, van Belkum A, Verbrugh H. Human factor in Staphylococcus aureus nasal carriage. Infect Immun 2004;72:6685-8.
187. Van den Akker EL, Nouwen JL, Melles DC et al. Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J Infect Dis 2006;194:814-18.
188. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996;156:1109-12.
189. Toshkova K, Annemuller C, Akineden O, Lammler C. The significance of nasal carriage of Staphylococcus aureus as risk factor for human skin infections. FEMS Microbiol Lett 2001;202: 17-24.
190. Baggett HC, Hennessy TW, Rudolph K et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565-73.
191. Kars M, van Dijk H, Salimans MM, Bartelink AK, van de Wiel A. Association of furunculosis and familial deficiency of mannose-binding lectin. Eur J Clin Invest 2005;35:531-4.
192. Zimakoff J, Rosdahl VT, Petersen W, Scheibel J. Recurrent staphylococcal furunculosis in families. Scand J Infect Dis 1988;20:403-5.
193. Nguyen DM, Mascola L, Brancoft E. Recurring methicillinresistant Staphylococcus aureus infections in a football team. Emerg Infect Dis 2005;11:526-32.
194. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants: Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR 2003;52:793-5.
195. Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-75.
196. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities: Georgia, California, and Texas, 2001-2003. MMWR 2003;52: 992-6.
197. Nolte O, Haag H, Zimmerman A, Geiss HK. Staphylococcus aureus positive for Panton-Valentine leukocidin genes but susceptible to methicillin in patients with furuncles. Eur J Clin Microbiol Infect Dis 2005;24:477-9.
198. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;4:CD003340.
199. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003;37: 933-8.
200. Simor AE, Phillips E, McGeer A et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178-85.
201. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988;260:2682- 5.
202. Walsh TJ, Standiford HC, Reboli AC et al. Randomized doubleblinded trial of rifampin with either novobiocin or trimethoprim- sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993;37:1334-42.
203. Parras F, Guerrero MC, Bouza E et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175-9.
204. Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am J Infect Control 2007;35:106-14.
205. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31.
206. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-9.
207. Fortun J, Navas E, Martinez-Beltran J et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001;33:120-5.
208. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6.
209. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
210. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
211. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl 5):S341-S353.
212. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
213. Stryjewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005;40:1601-7.
214. Stryjewski ME, Chu VH, O'Riordan WD et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50: 862-7.
215. Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, doubleblind comparison of once-weekly dalbavancin versus twicedaily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15.
216. Ward KE, Mersfelder TL, LaPlante KL. Oritavancin: an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006;15:417-29.
217. Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007;16:1441-8.
218. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51:3612-16.
219. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA betalactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007;16:419-29.
220. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007;13(suppl 2):25-9.
221. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
222. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children's Hospital. Arch Pediatr Adolesc Med 2005;159:980- 5.
223. Milatovic D, Braveny I, Verhoef J. Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother 1983;24:413-17.
224. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-8.
225. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005;40:1429- 34.